Nektar Therapeutics
Update in progressNKTR (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Nektar Therapeutics is a biopharmaceutical company focused on immunotherapy research and development. Its pipeline includes rezpegaldesleukin (Phase 2b) for autoimmune and inflammatory disorders; NKTR-0165 for ulcerative colitis, vitiligo and multiple sclerosis; NKTR-0166 for autoimmune disease; NKTR-422 for fibrotic diseases; and NKTR-255 for solid tumors and diffuse large B-cell lymphoma. It collaborates with Takeda, AstraZeneca, UCB, Roche, Bausch Health, Pfizer, Bristol-Myers Squibb and Merck KGaA. Founded 1990, based in San Francisco.
Company score
- Sentiment
- 0.34
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.22
- Governance
- 0.03
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.07
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.21
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationUnited States
- CEOMr. Howard W. Robin
- Founded1990
- Employees63
- Websitewww.nektar.com
Identifiers
- ISINUS6402683063
- FIGIBBG000BHCYJ1
- CUSIP457191104
- CIK0000906709